Transcode Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed July 23, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 28/100
What the filing says
CK Life Sciences Intl (Holdings) Inc filed an amended Schedule 13D/A on July 23, 2026, regarding its beneficial ownership stake in Transcode Therapeutics, Inc. The filing does not disclose specific share counts, ownership percentages, dollar amounts, or the nature of the amendments made in this document. Without access to the detailed amendment contents, the concrete changes to the ownership position cannot be determined.
Why this rating
Schedule 13D amendments are routine regulatory disclosures when 5%+ holders update positions. Without specific percentage, share, or valuation data showing material change, this is standard SEC filing activity relative to the $6.5M market cap company.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.